Ito T - Search Results

1

Patient Preferences for Metastatic Hormone-Sensitive Prostate Cancer Treatments: A Discrete Choice Experiment Among Men in Three European Countries.

de Freitas HM, Ito T, Hadi M, Al-Jassar G, Henry-Szatkowski M, Nafees B, Lloyd AJ. de Freitas HM, et al. Among authors: ito t. Adv Ther. 2019 Feb;36(2):318-332. doi: 10.1007/s12325-018-0861-3. Epub 2019 Jan 7. Adv Ther. 2019. PMID: 30617763 Free PMC article.

2

Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: A network meta-analysis.

Feyerabend S, Saad F, Li T, Ito T, Diels J, Van Sanden S, De Porre P, Roiz J, Abogunrin S, Koufopoulou M, Fizazi K. Feyerabend S, et al. Among authors: ito t. Eur J Cancer. 2018 Nov;103:78-87. doi: 10.1016/j.ejca.2018.08.010. Epub 2018 Sep 12. Eur J Cancer. 2018. PMID: 30218976 Free article.

3

Qualitative and Quantitative Assessment of Patient and Carer Experience of Chemotherapy (Docetaxel) in Combination with Androgen Deprivation Therapy (ADT) for the Treatment of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC).

Ito T, Grant L, Duckham BR, Ribbands AJ, Gater A. Ito T, et al. Adv Ther. 2018 Dec;35(12):2186-2200. doi: 10.1007/s12325-018-0825-7. Epub 2018 Nov 10. Adv Ther. 2018. PMID: 30415297 Free PMC article.

4

Estimating utilities/disutilities for high-risk metastatic hormone-sensitive prostate cancer (mHSPC) and treatment-related adverse events.

Hall F, de Freitas HM, Kerr C, Ito T, Nafees B, Lloyd AJ, Penton J, Hadi M, Lanar S, Pham TP. Hall F, et al. Among authors: ito t. Qual Life Res. 2019 May;28(5):1191-1199. doi: 10.1007/s11136-019-02117-9. Epub 2019 Feb 14. Qual Life Res. 2019. PMID: 30767088 Free PMC article. Review.

5

Adjusting Overall Survival Estimates for Treatment Switching in Metastatic, Castration-Sensitive Prostate Cancer: Results from the LATITUDE Study.

Feyerabend S, Saad F, Perualila NJ, Van Sanden S, Diels J, Ito T, De Porre P, Fizazi K. Feyerabend S, et al. Among authors: ito t. Target Oncol. 2019 Dec;14(6):681-688. doi: 10.1007/s11523-019-00685-x. Target Oncol. 2019. PMID: 31754962 Free PMC article. Clinical Trial.

6

Treatment-Resistant Depression in Real-World Clinical Practice: A Systematic Literature Review of Data from 2012 to 2022.

Oliveira-Maia AJ, Bobrowska A, Constant E, Ito T, Kambarov Y, Luedke H, Mulhern-Haughey S, von Holt C. Oliveira-Maia AJ, et al. Among authors: ito t. Adv Ther. 2024 Jan;41(1):34-64. doi: 10.1007/s12325-023-02700-0. Epub 2023 Oct 26. Adv Ther. 2024. PMID: 37882883 Free PMC article. Review.

7

Daratumumab monotherapy compared with historical control data in heavily pretreated and highly refractory patients with multiple myeloma: An adjusted treatment comparison.

Usmani SZ, Diels J, Ito T, Mehra M, Khan I, Lam A. Usmani SZ, et al. Among authors: ito t. Am J Hematol. 2017 Aug;92(8):E146-E152. doi: 10.1002/ajh.24781. Epub 2017 Jun 5. Am J Hematol. 2017. PMID: 28474745 Free PMC article.

8

Comparative Efficacy of Daratumumab Monotherapy and Pomalidomide Plus Low-Dose Dexamethasone in the Treatment of Multiple Myeloma: A Matching Adjusted Indirect Comparison.

Van Sanden S, Ito T, Diels J, Vogel M, Belch A, Oriol A. Van Sanden S, et al. Among authors: ito t. Oncologist. 2018 Mar;23(3):279-287. doi: 10.1634/theoncologist.2017-0103. Epub 2017 Nov 30. Oncologist. 2018. PMID: 29192016 Free PMC article.

9

Adjusted comparison of daratumumab monotherapy versus real-world historical control data from the Czech Republic in heavily pretreated and highly refractory multiple myeloma patients.

Jelínek T, Maisnar V, Pour L, Špička I, Minařík J, Gregora E, Kessler P, Sýkora M, Fraňková H, Adamová D, Wróbel M, Mikula P, Jarkovský J, Diels J, Gatopoulou X, Veselá Š, Besson H, Brožová L, Ito T, Hájek R. Jelínek T, et al. Among authors: ito t. Curr Med Res Opin. 2018 May;34(5):775-783. doi: 10.1080/03007995.2017.1410121. Epub 2018 Feb 15. Curr Med Res Opin. 2018. PMID: 29172760

10

A conceptual model for chronic hepatitis B and content validity of the Hepatitis B Quality of Life (HBQOL) instrument.

Abbott J, Aldhouse NVJ, Kitchen H, Pegram HC, Brown F, Macartney M, Villasis-Keever A, Sbarigia U, Ito T, Chan EKH, Kennedy PT. Abbott J, et al. Among authors: ito t. J Patient Rep Outcomes. 2024 Mar 4;8(1):29. doi: 10.1186/s41687-023-00675-8. J Patient Rep Outcomes. 2024. PMID: 38436804 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

11,355 results

Search Page